Immunotherapies + Other Therapies
Chemotherapy, in combination with immunotherapeutic approaches such as PD-L1 inhibition, may augment the immune response to cancer1:
+ Small molecule
One approach within immuno-oncology is to combine blockade of multiple immune checkpoints with small-molecule targeted therapies.2
Many targeted therapies modulate immune response (eg, T-cell proliferation and responsiveness to tumor antigens). This makes them attractive candidates for combination with immunotherapy because of the potential for additive effects.3
PD-L1=programmed cell death ligand-1; EGFR=epidermal growth factor receptor; MEK=MAPK/ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase) kinase; VEGFR=vascular endothelial growth factor receptors; PARP=poly ADP ribose polymerase.
1. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013;19(5):1021-1034. 2. Vanneman M, Drandoff G. Combing immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237-251. 3. AstraZeneca. Clinical trials appendix Q1 2017 results update. https://www.astrazeneca.com/content/dam/az/PDF/2017/QR1/Q1_2017_Results_Clinical_Trial_Appendix.pdf. Accessed July 7, 2017.